



FDA Approves the First Flu Vaccine for At Home Use, Providing a Needle Free Option Outside of Traditional Health Care Settings

October 10, 2024

Reading Time : **1 min**

By: Nathan A. Brown, Marlee P. Gallant, Caroline D. Kessler, Olive Lee

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at-home use.

The vaccine, FluMist, is administered by nasal spray and prevents the flu by using a weakened form of live influenza virus strains A and B to create a lasting immune response. FluMist was initially approved by FDA in 2003 for individuals ages 5 to 49, and in 2007, FDA extended the approval of its use to children ages 2 to 5. Until recently, the vaccine could only be administered by medical providers at a doctor's office or pharmacy. FDA expects that this new option for receiving a flu vaccine with potentially greater convenience and flexibility will increase access.

Under the new approval, FluMist may be self-administered by adults up to 49 years of age or administered by a caregiver for those between ages 2 through 17. A prescription is still required, however, for at-home use. Beginning next fall, individuals 18 years and older will be able to order FluMist through a third-party online pharmacy by visiting FluMist's website and completing an eligibility assessment. If they are eligible, a pharmacist will approve their order, and the vaccine will be shipped to them.

The vaccine is expected to be available for at-home use for the 2025-26 flu season.

Categories

Health Care

Regulatory

Food and Drug Administration (FDA)

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.